Lymphodepletion dosing regimens for cellular immunotherapies

The present invention encompasses methods and compositions including genetically- modified cells expressing chimeric antigen receptors or exogenous T cell receptors, and pharmaceutical compositions thereof, for the treatment of cancer and other disorders and diseases. Further, provided herein are me...

Full description

Saved in:
Bibliographic Details
Main Author MCCREEDY Jr., Bruce J
Format Patent
LanguageEnglish
Published 31.03.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention encompasses methods and compositions including genetically- modified cells expressing chimeric antigen receptors or exogenous T cell receptors, and pharmaceutical compositions thereof, for the treatment of cancer and other disorders and diseases. Further, provided herein are methods for depleting lymphocytes in a subject in need of treatment prior to, concomitant with, or following administration of the genetically- modified cells provided herein.
Bibliography:Application Number: AU20200333851